Arkin Amends UroGen Pharma Stake Filing

TL;DR

**Moshe Arkin updated his UroGen Pharma ownership filing, signaling a change in his stake.**

AI Summary

Moshe Arkin, through Arkin Communications Ltd., filed an Amendment No. 4 to Schedule 13D for UroGen Pharma Ltd. on February 22, 2024. The filing indicates a change in beneficial ownership of UroGen Pharma Ltd.'s Ordinary Shares, par value NIS 0.01 per share, with the event requiring the filing occurring on July 28, 2023. The filing updates information regarding Arkin's holdings in the pharmaceutical company.

Why It Matters

This filing updates the public record on a significant shareholder's position in UroGen Pharma, which can influence investor perception and potentially the company's strategic direction.

Risk Assessment

Risk Level: low — This is an informational filing about a change in beneficial ownership, not an event that inherently carries high risk.

Key Numbers

• NIS 0.01 — Par Value per Share (Ordinary Shares of UroGen Pharma Ltd.)

Key Players & Entities

• Moshe Arkin (person) — Filing Person/Beneficial Owner
• Arkin Communications Ltd. (company) — Filing Group Member
• UroGen Pharma Ltd. (company) — Subject Company/Issuer
• Goldfarb Gross Seligman & Co. (company) — Legal Counsel
• Perry Wildes (person) — Legal Counsel Contact

FAQ

Filing Documents

• zk2431036.htm (SC 13D/A) — 45KB
• 0001178913-24-000695.txt ( ) — 46KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby restated in its entirety to read as follows

Item 5 of the Schedule 13D is hereby restated in its entirety to read as follows: (a) and (b) As of February 22, 2024, Arkin Communications owned directly (and therefore was deemed the beneficial owner of) 1,369,315 Ordinary Shares, which represented approximately 4.44% of the number of Ordinary Shares outstanding. In addition, Arkin Communications has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Communications. As the sole shareholder and sole director of Arkin Communications, Mr. Arkin may be deemed to be the indirect beneficial owner of the Ordinary Shares beneficially owned by Arkin Communications. In addition, Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Communications. (c) To the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares. (d) No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5. (e) To the best knowledge of the Reporting Persons, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Ordinary Shares on July 28, 2023. Percentages set forth in this Schedule 13D (Amendment No. 4) were calculated based on 30,866,320 Ordinary Shares issued and outstanding as of November 7, 2023, as provided in the Issuer's Form 10-Q filed on November 14, 2023.

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits. The following Exhibits are filed herewith: 1 Joint Filing Agreement, dated as of May 30, 2017, by and among the Reporting Persons (incorporated by reference to Exhibit 1 of the Original Schedule 13D). 2 Board resolution of Arkin Communications Ltd. (incorporated by reference to Exhibit 2 of the Original Schedule 13D). 4

Signatures

Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. Dated : February 22, 2024 Arkin Communications Ltd. /s/ Moshe Arkin Name: Moshe Arkin Title: Director Moshe Arkin /s/ Moshe Arkin 5